[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Gottfried von Keudell, MD PhD\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":86},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,44,65],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100602832","phase-2-odronextamab-in-low-tumor-volume-advanced-fl-100602832",false,"NCT07128641","Odronextamab in Low Tumor Volume Advanced FL","A Phase II Study of Odronextamab in Treatment Naïve Patients With Low Tumor Volume Advanced Stage Follicular Lymphoma","Inclusion Criteria:\n\n* Biopsy-confirmed (fresh or archival tissue) follicular lymphoma grade 1-3A that is CD20+ (by immunophenotype or immunohistochemistry) at time of diagnosis. All degrees of CD20 positivity will be accepted.\n* Lymph node biopsy obtained in the previous 6 months\n* Subjects must have measurable disease at time of enrollment as defined by at least one lymph node with long axis ≥1.5 cm\n* Age ≥18 years\n* ECOG performance status \\> 2\n* Life expectancy of \\> 2 years\n* Participants must meet the following organ and marrow function as defined below:\n\n  * Absolute neutrophil count ≥1000 cells\u002Fmcl\n  * Platelets ≥100,000 cells\u002Fmcl\n  * Hemoglobin ≥ 10 g\u002FdL\n* Adequate organ function, as documented by:\n\n  * Cardiac ejection fraction \\>40% by echocardiogram or multi-gated acquisition (MUGA) scan\n  * Total bilirubin ≤1.5 × upper limit of normal (ULN) (≤3 × ULN if attributed to lymphoma infiltration of liver)\n  * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3 × ULN (≤5 × ULN if attributed to lymphoma infiltration of liver)\n  * Alkaline phosphatase (ALP) ≤2.5 × ULN (≤5 × ULN if attributed to lymphoma infiltration of liver)\n  * Calculated creatinine clearance by Cockcroft Gault formula ≥40 mL\u002Fmin\n  * NOTE: Irrespective of the presence of lymphoma infiltration of the liver, a participant with an AST \\>3 × ULN and\u002For ALT \\>3 × ULN concurrent with a total bilirubin \\>1.5 × ULN will be excluded.\n  * NOTE: Participants with known Gilbert syndrome will be excluded if the total bilirubin value is \\>4 × ULN.\n  * NOTE: Participants with a calculated creatinine clearance\n* Patients with hepatitis B core antibody positivity with negative PCR on antiviral therapy will be eligible but will be required to receive appropriate antiviral prophylaxis as described in Section 5.2. Patients with Hepatitis C antibody must have undetectable viral load.\n* Women of childbearing potential (WOCBP)\\* must agree to practice highly effective contraception prior to the initial dose\u002Fstart of the first treatment, during the study, and for at least 6 months after the last dose of odronextamab. Egg donation is prohibited during the study and for 6 months after the last dose of the assigned study treatment. Highly effective contraceptive measures include:\n\n  * stable use of combined (estrogen and progestogen containing) hormonal contraception (oral, intravaginal, transdermal) or progestogen-only hormonal contraception (oral, injectable, implantable) associated with inhibition of ovulation initiated 2 or more menstrual cycles prior to screening.\n  * intrauterine device (IUD); intrauterine hormone-releasing system (IUS)\n  * bilateral tubal ligation\u002Focclusion\n  * vasectomized partner (provided that the male vasectomized partner is the sole sexual partner of the WOCBP study participant and that the vasectomized partner has obtained medical assessment of surgical success for the procedure)\n  * sexual abstinence†, ‡.\n  * A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a postmenopausal state in women not using hormonal contraception or hormonal replacement therapy. However, in the absence of 12 months of amenorrhea, a single FSH measurement is insufficient to determine the occurrence of a postmenopausal state. The above definitions are according to the Clinical Trial Facilitation Group guidance. Pregnancy testing and contraception are not required for women with documented hysterectomy.\n\n    * WOCBP are defined as women who are fertile following menarche until becoming postmenopausal, unless permanently sterile. Permanent sterilization methods include hysterectomy, bilateral salpingectomy, and bilateral oophorectomy.\n\n      * Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the assigned study treatments. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the subject.\n\n        * Periodic abstinence (calendar, symptothermal, post-ovulation methods), withdrawal (coitus interruptus), spermicides only, and lactational amenorrhea method (LAM) are not acceptable methods of contraception. Female condom and male condom should not be used together.\n* WOCBP must have negative serum pregnancy test at screening.\n* Sexually active adult men must agree to use the following forms of medically acceptable birth control: consistent use of a condom OR vasectomy with medical assessment of surgical success, prior to initial dose, during the study and for at least 6 months following the last dose of odronextamab. Sperm donation is prohibited following odronextamab administration throughout the study and for at least 6 months following the last dose of odronextamab administration.\n* Ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n* Participants must not meet any GELF Criteria for high tumor volume, or other circumstances for which immediate therapy would be indicated\n\n  * Any nodal or extranodal tumor mass \\>7 cm diameter\n  * Involvement of at least 3 nodal sites, each with diameter \\>3 cm\n  * Presence of any systemic or B symptoms for greater than 2 weeks (fever, night sweats, or weight loss)\n  * Splenic enlargement with inferior margin below the umbilical line\n  * Compression syndrome (ureteral, orbital, gastrointestinal)\n  * Pleural or peritoneal serous effusion (irrespective of cell content)\n  * Leukemic phase (\\>5.0 x10⁹\u002FL circulating malignant cells)\n  * Cytopenia (granulocyte count \\\u003C 1.0x10⁹\u002FL and\u002For platelets \\\u003C 100x10⁹\u002FL)\n* Infections:\n\n  * Evidence of any active infection (bacterial, viral, fungal, mycobacterial, parasitic or other) at study enrollment or within 2 weeks of study enrollment, if requiring ongoing treatment and\u002For has the potential to cause disseminated disease or severe infection upon immunosuppression. There should be evidence that the infection has cleared or is well controlled by start of study therapy.\n  * Active symptomatic COVID-19 infection. Note, patients with prolonged PCR positivity (\\>2 weeks after initial diagnosis) may be allowed to participate following discussion with the PI\n  * Uncontrolled infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) NOTE: Participants with HIV who have controlled infection (undetectable viral load and CD4 count above 350 cells\u002FμL either spontaneously or on a stable antiviral regimen) are permitted NOTE: Participants who are hepatitis B surface antigen positive or who are hepatitis B core antibody positive should undergo evaluation by a specialist and be considered to have controlled infection (serum hepatitis B virus DNA PCR that is below the limit of detection AND receiving anti-viral therapy for hepatitis B) before they are permitted onto study NOTE: Participants who are HCV antibody positive who have controlled infection (undetectable HCV RNA by PCR either spontaneously or in response to a successful prior course of anti-HCV therapy) are permitted\n* Another active malignancy (aside from B-cell NHL) in the past 2 years, with the following exceptions: non-melanoma skin cancer that has undergone potentially curative therapy, in situ cervical carcinoma, or any other tumor that has been deemed to be effectively treated with definitive local control and with curative intent.\n* Limited-stage follicular lymphoma (stage I and limited stage II) with a possibility of treatment with a curative intent using radiotherapy\n* Duodenal follicular lymphoma\n* Follicular lymphoma with spontaneous regression prior to treatment initiation\n* Patients who have had any prior systemic therapy for lymphoma, including rituximab and\u002For tazemetostat\n* Patients who have had prior radiation therapy, with the following exception: Low dose radiotherapy RT (2x2Gy, or 4Gy x 1) is allowed but must be completed at least 12 weeks prior to treatment on this study; patients must meet criteria for measurable\u002Fassessable disease as outlined above after completion of RT, and have a nodal evaluable disease outside the radiation area\n* Uncontrolled underlying cardiac conditions including but not limited to: congestive heart failure grade III or IV (by NYHA) or EF \\\u003C 45%, unstable angina pectoris, acute myocardial infarction \\\u003C 6 months, cardiac arrhythmia\n* History of uncontrolled neurologic condition including but not limited to: seizure disorder, stroke, psychosis, dementia, CNS vasculitis, encephalitis\n* Immunosuppressive therapy for non-lymphoma-related indication within 28 days of initiation of treatment, including systemic corticosteroids 10 mg\u002Fday or greater prednisone-equivalent\n* Patients with known or suspected CNS involvement or leptomeningeal disease are excluded\n* History of neurodegenerative condition or CNS movement disorder. Patients with a history seizure within 12 months prior to study enrollment are excluded.\n* Pregnant women or participants unwilling to adhere to institutional guidelines for highly effective contraception during odronextamab treatment and for 12 months after the last dose are excluded from this study because of documented (rituximab) and unknown risks of the treatment effect on fetal development.\n* Known current alcohol or drug abuse, psychiatric illness, or unstable social situation that is likely to limit compliance with study requirements\n* Allergy\u002Fhypersensitivity:\n\n  * Known hypersensitivity to both allopurinol and rasburicase\n  * History of allergic reactions or hypersensitivity attributed to compounds of similar chemical or biological components\n* Exposure to a live or a live attenuated vaccine within 4 weeks","ALL","18 Years",{"count":19,"type":20},35,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","The purpose of this study is to evaluate the safety and effectiveness of treating previously untreated Follicular Lymphoma (FL) with odronextamab.\n\nThe name of the study drug in this research study is:\n\n-Odronextamab (a type of monoclonal antibody)",[26,27],"Follicular Lymphoma","Lymphoma",[26,27,29,30],"Treatment-naive Follicular lymphoma","Advanced Stage Follicular Lymphoma","RECRUITING","2026-03-12",{"date":34,"type":35},"2026-03-13","ACTUAL",{"date":37,"type":35},"2025-09-08",{"date":39,"type":20},"2028-01-02",{"name":41,"class":42},"Gottfried von Keudell, MD PhD","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":21,"phases":53,"briefSummary":54,"conditions":55,"keywords":58,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":59,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":43},"100555301","phase-2-rituximab-plus-venetoclax-in-front-line-marginal-zone-lymphoma-100555301","NCT06510309","Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma","A Phase II Study Using Rituximab Plus Venetoclax in the Front Line Treatment of Marginal Zone Lymphoma","Inclusion Criteria:\n\n* Participants must have histologically confirmed Marginal Zone Lymphoma\n* Patients must have measurable disease as defined by at least one lymph node ≥1.5 cm or spleen \\> 13 cm\n* Patients with intestinal MALT lymphoma must have disease that is detectable by EGD or colonoscopy with biopsy\n* Patients with gastric MALT lymphoma must be h. pylori negative. Patients who are h. pylori positive are allowed if they have failed a trial of h. pylori eradication\n* Patients with gastric MALT lymphoma who are h. pylori negative or who relapsed\u002Frefractory disease after h. pylori eradication must be ineligible form have refused or failed gastric radiation therapy\n* Age ≥18 years\n* ECOG performance status ≤1\n* Life expectancy of greater than 2 years\n* Participants must meet the following organ and marrow function as defined below:\n\n  * Hemoglobin ≥8.0 g\u002FdL\n  * absolute neutrophil count ≥1,000 cells\u002FmcL (In the event of documented bone marrow involvement, ANC must be ≥1500 cells\u002FmcL)\n  * platelets ≥50,000 cells\u002Fmm3\n  * total bilirubin \\\u003C 1.5 x institutional upper limit of normal (ULN) (In patients with Gilberts disease or documented liver involvement, total bilirubin \\\u003C 3 X ULN will be allowed)\n  * AST(SGOT)\u002FALT(SGPT) \\\u003C 3 × institutional ULN unless elevation is caused by liver involvement with MZL\n  * Creatinine within institutional ULN OR creatinine clearance \\>60mL\u002Fmin for patients with creatinine levels above institutional normal (by Cockcroft-Gault estimate or 12-24h creatinine clearance measurements)\n* Ability to understand and the willingness to sign a written informed consent document\n* Patient must be able to swallow pills\n* HIV-positive patients on combination antiretroviral therapy are eligible if their HIV is under adequate control with an antiretroviral regimen that has been stable for \\> 4 weeks, as long as the CD4 count is \\>300. Appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated\n* Patients with Hepatitis B surface antibody serum positivity due to poor immunization, as well as those with Hepatitis B core antibody positivity with negative PCR on antiviral therapy will be eligible\n\nExclusion Criteria:\n\n* Patients who had prior systemic therapy including rituximab\n* Patients who have had prior radiation therapy, with the following exceptions:\n\n  * Palliative radiotherapy (RT) is allowed, but must be completed at least 1 week prior to treatment on this study, and prior to any baseline imaging studies or biopsies. Patients must meet criteria for measurable\u002Fassessable disease as outlined above after completion of RT.\n  * Prior RT for gastric MALT is allowed, but must be completed at least 1 week prior to treatment on this study, and prior to any baseline imaging studies or biopsies. Patients must meet criteria for measurable\u002Fassessable disease as outlined above after completion of RT.\n* Prior treatment with ibrutinib or other BTK inhibitor\n* Patients with h. pylori-associated gastric MALT or stage I\u002FII MZL will be excluded unless they are deemed to be unfit for radiation therapy with curative intent.\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements\n* Patients with uncontrolled hepatitis B or C or HIV infection are ineligible defined as patients with positive serologies and a detectable viral load by PCR.\n* Patients with Hep B core ab positivity are allowed provided Hep B PCR is undetectable\n* Pregnant women or participants unwilling to adhere to institutional guidelines for highly effective contraception for 12 months after the last dose of rituximab are excluded from this study because of documented risks of rituximab on fetal immunologic development and unknown effects of venetoclax on embryonic development. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with venetoclax, breastfeeding should be discontinued.\n* Received moderate or strong CYP3A inhibitors (such as fluconazole, ketoconazole, and clarithromycin) within 7 days prior to the first dose of venetoclax.\n* Received moderate or strong CYP3A inducers (such as rifampin, carbamazepine, phenytoin, St. John's Wort) within 7 days prior to the first dose of venetoclax.",{"count":52,"type":20},33,[23],"The purpose of this study is to see if the combination of rituximab and venetoclax is effective in treating participants with untreated Marginal Zone Lymphoma (MZL).\n\nThe names of the study drugs involved in this study are:\n\n* Venetoclax (a type of inhibitor)\n* Rituximab (a type of antibody)",[27,56,57],"Marginal Zone Lymphoma","MZL",[27,56,57],{"date":34,"type":35},{"date":61,"type":35},"2026-02-11",{"date":63,"type":20},"2031-10-01",{"name":41,"class":42},{"id":66,"slug":67,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":4,"eligibilityCriteria":71,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":72,"targetDuration":4,"studyType":21,"phases":74,"briefSummary":75,"conditions":76,"keywords":79,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":80,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":5},"100555315","phase-2-epcoritamab-in-previously-treated-wm-100555315","NCT06510491","Epcoritamab in Previously Treated WM","A Phase 2 Trial Investigating Epcoritamab in Patients With Previously Treated Waldenstrom Macroglobulinemia (WM)","Inclusion Criteria:\n\n* A diagnosis of lymphoplasmacytic lymphoma\u002FWM that is CD20+ by immunophenotype or immunohistochemistry confirmed by bone marrow biopsy\u002Faspirate (fresh or archival tissue acceptable) at time of most recent progression. All degrees of CD20 positivity will be accepted.\n* Serum IgM level \\>2x upper limit of normal (ULN)\n* Meeting criteria for initiation of treatment per IWWM2 criteria \\[Kyle Semin Oncol 2002\\], including but not limited to hyperviscosity syndrome, peripheral neuropathy, cold agglutinin disease, cryoglobulinemia, amyloidosis, cytopenias due to bone marrow infiltration, symptomatic or bulky lymph nodes, symptomatic splenomegaly, constitutional symptoms not otherwise explained by other causes, signs of organ dysfunction secondary to WM\n* At least one prior line of treatment that was discontinued either due to intolerance or disease progression\n* Prior therapies must have included an anti-CD20 antibody (e.g. rituximab) and a BTK inhibitor (e.g. ibrutinib, zanubrutinib). Patients who received ibrutinib and rituximab in combination as first line therapy will be eligible. BTKi should be stopped to allow a washout period of no less than 4 half-lives prior to epcoritamab.\n* Age ≥18 years\n* ECOG performance status £ 2\n* Life expectancy of greater than 2 years\n* Participants must meet the following organ and marrow function as defined below:\n\n  * absolute neutrophil count ≥1000 cells\u002Fmcl (G-CSF allowed)\n  * absolute lymphocyte count ≥200 cells\u002Fmcl\n  * platelets ≥75,000 cells\u002Fmcl OR ≥50,000 cells\u002Fmcl in the presence of bone marrow involvement or splenomegaly (Note: no PLT transfusions within 7 days prior to screening)\n  * hemoglobin ≥ 8 g\u002FdL (transfusion allowed)\n  * total bilirubin ≤ 1.5 institutional upper limit of normal (ULN). In patients with suspected\u002Fknown Gilbert's disease total bilirubin up to 3x ULN will be allowed but direct bilirubin must be ≤ 2 x ULN\n  * AST(SGOT)\u002FALT(SGPT) ≤3× institutional ULN\n  * creatinine ≤ institutional ULN OR\n  * creatinine clearance \\>45 ml\u002Fmin (by Cockcroft-Gault estimate or 24-hr creatinine clearance measurement)\n* Subject does not have an active (PCR-positive) Hepatitis B virus (HBV) or Hepatitis C virus (HCV) infection. If laboratory evidence for a chronic infection with hepatitis B, close monitoring and prophylactic therapy is required as described in Section 5.4.\n* Participants with a history of prior malignancy will be eligible if all treatment of that malignancy was completed at least 2 years before registration, the treatment was considered \"curable-intent\", and there is no evidence of disease.\n* Ability to understand and the willingness to sign a written informed consent document.\n* Females of childbearing potential must agree to practice a highly effective method of birth control (as defined by the EU Clinical Trial Facilitation Group) consistent with local regulations regarding the use of birth control methods for patients participating in clinical trials:\n\n  * Established use of oral, injected or implanted combined (estradiol and progesterone containing) hormonal contraception;\n  * Placement of an intrauterine device (IUD) or intrauterine system (IUS);\n  * Male partner sterilization (the vasectomized partner should be the sole partner for that patient)\n  * True abstinence (when this is in line with the preferred and usual lifestyle of the patient)\n* Women must agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction during the trial and for 12 months after receiving the last dose of epcoritamab. Men must also not donate sperm during the trial and for 12 months after receiving the last dose of epcoritamab.\n* A man who is sexually active with a woman of childbearing potential must agree to use a barrier method of birth control (i.e. use of condom) during the trial and for 12 months after receiving the last dose of epcoritamab.\n* Patients with HIV may be enrolled if they are on stable antiretroviral therapy, have an undetectable viral load, and CD4 count \\> 250 cells\u002Fmm3.\n\nExclusion Criteria:\n\n* Participants who have disease that has transformed to aggressive lymphoma\n* Participants with symptomatic or suspected hyperviscosity syndrome or IgM levels greater than 4000 mg\u002FdL who are unable to undergo plasmapheresis to decrease the risk of an IgM flare. Participants who can undergo plasmapheresis will be eligible as long as they undergo the procedure prior to first treatment dose.\n* Participants who are receiving any other investigational agent\n* Washout from prior therapy: BTKi: no less than5 half-lives prior to epcoritamab to prevent BTKi rebound and rituximab: no less than 4 weeks (28 days) from last dose.\n* Participants who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities \\> Grade 1) except for alopecia and peripheral neuropathy\n* Uncontrolled intercurrent active infection requiring hospitalization or intravenous antimicrobial agents within 4 weeks of start of treatment\n* Uncontrolled underlying cardiac conditions including but not limited to: congestive heart failure grade III or IV (by NYHA) or EF \\\u003C 45%, unstable angina pectoris, acute myocardial infarction \\\u003C 6 months, uncontrolled cardiac arrhythmia\n* History of uncontrolled neurologic condition including but not limited to: seizure disorder, stroke, psychosis, dementia, CNS vasculitis, encephalitis\n* Need for supplemental O2 at rest to maintain SaO2\\>92%\n* Chronic immunosuppressive therapy for non-WM-related indication within 28 days of initiation of treatment, including systemic corticosteroids 20 mg\u002Fday or greater prednisone-equivalent\n* Patients with known or suspected CNS involvement or leptomeningeal disease (i.e. BingNeel Syndrome) are excluded given concern for potentially increased risk of neurologic toxicity with epcoritamab. Patients with history of CNS malignancy from separate malignancy must have completed CNS-directed therapy and must currently have no evidence of disease\n* Pregnant or breastfeeding women or participants unwilling to adhere to institutional guidelines for highly effective contraception for the duration of the therapy are excluded. This is because of the unknown but potential risk of teratogenic or abortifacient effects, as well as potential for adverse events in nursing infants secondary to treatment of the mother, as epcoritamab has not yet been studied in this patient population. A female can be determined to not be of childbearing potential if she meets any of the following criteria:\n\n  * Premenarchal\n  * Postmenopausal (\\>45 years of age with amenorrhea for at least 12 months or any age with amenorrhea for at least 6 months and a serum follicle stimulating hormone \\[FSH\\] level \\>40 IU\u002FL or mIU\u002FmL)\n  * Permanently sterilized (e.g., bilateral tubal occlusion \\[which includes tubal ligation procedures as consistent with local regulations\\], hysterectomy, bilateral salpingectomy, bilateral oophorectomy) Note: If the childbearing potential changes after start of the trial (e.g., woman who is not heterosexually active becomes active, premenarchal woman experiences menarche) a woman must begin a highly effective method of birth control, as described under 3.1.13.\n* Known current alcohol or drug abuse, psychiatric illness, or unstable social situation that is likely to limit compliance with study requirements\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to epcoritamab\n* Exposure to a live or a live attenuated vaccine within 4 weeks",{"count":73,"type":20},20,[23],"This study is being done to determine if epcoritamab can be used to treat participants with previously treated Waldenstrom Macroglobulinemia (WM).\n\nThe names of the study drug involved in this study is:\n\n-Epcoritamab (a type of antibody)",[77,78],"Waldenstrom Macroglobulinemia","B-Cell Lymphoproliferative Disorder",[77,78],{"date":34,"type":35},{"date":82,"type":35},"2024-12-06",{"date":84,"type":20},"2027-12-31",{"name":41,"class":42},""]